Petros Pharmaceuticals Inc - PTPI Earnings per share for the trailing year

Petros Pharmaceuticals (PTPI) is expanding Stendra sales and digital services for the B2B segment. However, generic competition and marketing costs for new products are limiting potential. High customer acquisition costs online are reducing overall profitability. The value of 0.00 shapes the current metric, which clearly demonstrates the historical YoY EPS growth over the last 12 months on this chart.
Petros Pharmaceuticals Inc - analytical breakdowns and key metrics (PTPI)

Net income per share dynamics determine the fundamental stability of the business. This metric measures the percentage change in trailing twelve-month (TTM) income, neutralizing the seasonal fluctuations of quarterly reporting. By analyzing the TTM EPS growth chart, an investor can see the real return on assets. For Petros Pharmaceuticals (PTPI), this trend confirms the efficiency of its digital platforms. Direct online sales allow the company to scale profits without a proportional increase in operating expenses.